A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure.

导出 LinkOut

翻译打印收藏纠错

第一作者： Daniel J,Lenihan

第一单位： Division of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee.

作者： Daniel J,Lenihan ^[1] ; Sarah A,Anderson ^[1] ; Carrie Geisberg,Lenneman ^[1] ; Evan,Brittain ^[1] ; James A S,Muldowney ^[1] ; Lisa,Mendes ^[1] ; Ping Z,Zhao ^[2] ; Jennifer,Iaci ^[2] ; Stephen,Frohwein ^[3] ; Ronald,Zolty ^[4] ; Andrew,Eisen ^[2] ; Douglas B,Sawyer ^[5] ; Anthony O,Caggiano ^[2]

作者单位： Division of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee. ^[1] Acorda Therapeutics, Inc., Ardsley, New York. ^[2] Emory Heart and Vascular Center at Emory Saint Joseph's, Atlanta, Georgia. ^[3] University of Nebraska Medical Center, Omaha, Nebraska. ^[4] Maine Medical Center, Portland, Maine. ^[5]

关键词 AE, adverse event AUC, area under the curve DLT, dose-limiting toxicity GGF, glial growth factor HF, heart failure LVEF, left ventricular ejection fraction LVSD, left ventricular systolic dysfunction NRG, neuregulin NYHA, New York Heart Association functional class TEAE, treatment-emergent adverse event cardiac repair growth factor neuregulin systolic dysfunction

DOI 10.1016/j.jacbts.2016.09.005

PMID 30167542

发布时间 2023-09-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览5

JACC. Basic to translational science

2016年1卷7期

576-586页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure.

JACC. Basic to translational science

相似文献

JACC. Basic to translational science

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure.

JACC. Basic to translational science

相似文献

JACC. Basic to translational science

相关期刊

检索历史清除